• LAST PRICE
    2.1300
  • TODAY'S CHANGE (%)
    Trending Down-0.1400 (-6.1674%)
  • Bid / Lots
    2.1200/ 1
  • Ask / Lots
    2.1700/ 3
  • Open / Previous Close
    2.3600 / 2.2700
  • Day Range
    Low 2.1000
    High 2.3800
  • 52 Week Range
    Low 0.6534
    High 4.0000
  • Volume
    33,805
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.27
TimeVolumeBYSI
09:32 ET8072.38
09:39 ET2412.2668
09:48 ET1002.2935
09:56 ET35072.27
10:01 ET2002.27
10:06 ET1002.26
10:17 ET4072.3
10:21 ET2002.28
10:32 ET43282.27
10:44 ET2002.26
10:48 ET4442.25
10:53 ET2002.25
11:09 ET3002.265
11:15 ET2002.27
11:56 ET10002.27
11:58 ET8452.29
12:02 ET13002.27
12:07 ET2222.3
12:25 ET34262.2601
12:43 ET1002.26
01:03 ET1002.26
01:10 ET6002.2672
01:14 ET1162.26
01:24 ET1002.26
01:44 ET1002.26
02:00 ET20392.2746
02:04 ET1002.24
02:22 ET1002.24
02:42 ET1002.24
03:00 ET16952.23
03:02 ET10002.22
03:16 ET11002.1
03:23 ET4092.17
03:27 ET6112.17
03:30 ET6002.1325
03:32 ET2002.155
03:41 ET11002.17
03:43 ET1002.18
03:45 ET1002.14
03:48 ET1002.15
03:56 ET1002.165
03:57 ET8712.14
03:59 ET7732.13
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBYSI
Beyondspring Inc
82.9M
-3.0x
---
United StatesMIST
Milestone Pharmaceuticals Inc
81.9M
-1.1x
---
United StatesPVCT
Provectus Biopharmaceuticals Inc
83.3M
-26.9x
---
United StatesBTAI
BioXcel Therapeutics Inc
87.9M
-0.4x
---
United StatesIFRX
InflaRx NV
78.3M
-1.6x
---
United StatesSLS
Sellas Life Sciences Group Inc
82.2M
-1.1x
---
As of 2024-04-28

Company Information

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Contact Information

Headquarters
100 Campus Drive West Side, 4Th Floor, Suite 410FLORHAM PARK, NJ, United States 07932
Phone
646-528-4184
Fax
---

Executives

Chairperson of the Board, Chief Executive Officer, Co-Founder
Lan Huang
Chief Scientific Officer
G. Kenneth Lloyd
Director
Sihai Xu
Independent Director
Brendan Delaney
Independent Director
Patrick Fabbio

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$82.9M
Revenue (TTM)
$1.6M
Shares Outstanding
38.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.28
EPS
$-0.70
Book Value
$-0.15
P/E Ratio
-3.0x
Price/Sales (TTM)
53.5
Price/Cash Flow (TTM)
---
Operating Margin
-1,930.00%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.